BigHat Biosciences is a biotech company founded in 2019 designing safer, more effective next-generation antibody therapies for patients with the combination of machine learning and synthetic biology. BigHat integrates a wet lab for high-speed characterization with machine learning technologies to guide the search for better antibodies.

The company is currently developing several programs both internally and through partnerships with large pharmaceutical partners.